Split History
ETFs Holding CLDX »    CLDX Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Celldex Therapeutics is a biopharmaceutical company focused on the development and commercialization of immunotherapies and other targeted biologics. Co. is focusing on the research and development of: CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3; CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses its proprietary anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. According to our CLDX split history records, Celldex Therapeutics has had 2 splits.
CLDX split history picture
Celldex Therapeutics (CLDX) has 2 splits in our CLDX split history database. The first split for CLDX took place on March 10, 2007. CLDX's second split took place on February 11, 2019. This was a 1 for 15 reverse split, meaning for each 15 shares of CLDX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.

When a company such as Celldex Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the CLDX split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Celldex Therapeutics shares, starting with a $10,000 purchase of CLDX, presented on a split-history-adjusted basis factoring in the complete CLDX split history. CLDX split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/14/2011
End date: 04/13/2021
Start price/share: $61.35
End price/share: $21.47
Dividends collected/share: $0.00
Total return: -65.00%
Average Annual Total Return: -9.96%
Starting investment: $10,000.00
Ending investment: $3,500.30
Years: 10.01
Date Ratio
03/10/20071 for 1
02/11/20191 for 15
CLDX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CLRB Split History
CLRBW Split History
CLSN Split History
CMD Split History
CMN Split History
CNC Split History
CNDO Split History
CNMD Split History
COO Split History
COV Split History

Also explore: CLDX shares outstanding history

Aviat Networks, Inc. (AVNW)
Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
MicroSectors FANG+ Index 2X Leveraged ETNs due January 8, 2038 (FNGO)
MicroSectors FANG+ Index 3X Leveraged ETNs due January 8, 2038 (FNGU)
Moleculin Biotech, Inc. (MBRX)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CLDX Insider Buying

CLDX Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.